subscribeSubscribe
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
BUSINESSWIRE
26 Oct 2023
Share Share
Revance`s Botox rival gets FDA approval for painful neck muscle condition

Revance`s Botox rival gets FDA approval for painful neck muscle condition
REUTERS
15 Aug 2023
Share Share
Revance`s Biologic DAXXIFY (daxibotulinumtoxinA) Receives Approval in the U.S.

Revance`s Biologic DAXXIFY (daxibotulinumtoxinA) Receives Approval in the U.S.
FDA
11 Aug 2023
Share Share
Revance to Present Data on DAXXIFY for Injection for the Treatment of Cervical Dystonia

Revance to Present Data on DAXXIFY for Injection for the Treatment of Cervical Dystonia
BUSINESSWIRE
23 Feb 2023
Share Share
Revance to Present Data on the Efficacy & Safety of DAXXIFY for ASDS Meeting

Revance to Present Data on the Efficacy & Safety of DAXXIFY for ASDS Meeting
BUSINESSWIRE
10 Oct 2022
Share Share
Revance Announces Publications Highlighting the Efficacy Profile of DAXXIFY

Revance Announces Publications Highlighting the Efficacy Profile of DAXXIFY
BUSINESSWIRE
19 Sep 2022
Share Share
Brand Institute Partners on Brand Name and Nonproprietary

Brand Institute Partners on Brand Name and Nonproprietary
PRNEWSWIRE
12 Sep 2022
Share Share
U.S. FDA approves Revance`s Botox rival

U.S. FDA approves Revance`s Botox rival
HEALTH ET
09 Sep 2022
Share Share
Revance Announces FDA Approval of DAXXIFY for Injection

Revance Announces FDA Approval of DAXXIFY for Injection
BUSINESSWIRE
08 Sep 2022
Share Share
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
BUSINESSWIRE
09 Aug 2022
Share Share